heroin; metabolites; pharmacokinetics; inhalation; polydrug use
Abstract :
[en] The objective of the present study was to verify if severe physical health problems frequently encountered in heroin addicts and the concomitant use of alcohol and legal or illegal drugs other than heroin influenced the pharmacokinetics of the major metabolites of heroin. We conducted a 90 minutes follow-up of the plasma concentrations of the pharmaceutical heroin, named diacetylmorphine (DAM), in patients recruited in a DAM assisted treatment centre. TADAM (Traitement Assisté par DiAcétylMorphine) aimed to compare the efficacy of heroin-assisted treatment (HAT) compared with methadone maintenance treatment (MMT) for heroin users considered as treatment resistant patients and who have severe physical and mental health problems. Eleven patients were recruited. Blood samples were collected at baseline and 15, 45 and 90 minutes after DAM administration. All patients received DAM by the "chasing the dragon" route. Plasma samples were analyzed by a previously described ultra-high pressure liquid chromatography coupled to tandem mass spectrometry (UHPLC/MS-MS) method. A principal component analysis (PCA) was performed and 8 metabolite concentrations ratios were calculated to evaluate the influence of various factors (DAM dose, patient pathologies, concomitant use of medications, methadone, street heroin, alcohol and cocaine) on heroin metabolite pharmacokinetics. It seemed to be not affected by the DAM dose, patient pathologies and the concomitant use of medications, methadone, street heroin and alcohol. Cocaine use was the only parameter which showed differences in heroin pharmacokinetics.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
DUBOIS, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > Toxicologie clinique
Demaret, Isabelle ; Université de Liège - ULiège > Département des sciences cliniques > Psychiatrie et psychologie médicale
ANSSEAU, Marc ; Centre Hospitalier Universitaire de Liège - CHU > Psychiatrie et psychologie médicale
Rozet, Eric ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Hubert, Philippe ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Charlier, Corinne ; Université de Liège - ULiège > Département de pharmacie > Chimie toxicologique
Language :
English
Title :
Plasma level monitoring of the major metabolites of diacetylmorphine (heroin) by the "chasing the dragon" route in severe heroin addicts
European Monitoring Centre for Drugs and Drug Addiction. Annual Report 2010: The State of the Drugs Problem in Europe. Publications Office of the European Union, Luxembourg, 2011.
Robaeys G, Matheï C, van Ranst M, Buntinx F. Substance use in Belgium: Prevalence and management. Acta Gastroenterol Belg 2005; LXVIII: 46-49.
Charlier C, Dessalles MC, Plomteux G. Methadone maintenance treatment: is it possible to adapt the daily doses to the metabolic activity of the patient? Ther Drug Monit 2001; 23: 1-3.
Perneger T, Giner F, del Rio M, Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998; 317: 13-18.
van den Brinck W, Hendriks V, Blanken P, Koeter M, van Zwieten B, van Ree J. Medical prescription of heroin to treatment resistant heroin addicts: two randomized controlled trials. BMJ 2003; 327: 310-316.
March J, Oviedo-Joekes E, Perea-Milla E, Carrasco F, the PEPSA team. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat 2006; 31: 203-211.
Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence. Br J Psychiatry 2007; 191: 55-62.
Oviedo-Joekes E, Nosyk B, Marsh D, Guh D, Brissette S, Gartry C et al. Scientific and political challenges in North America's first randomized controlled trial of heroin assisted-treatment for severe heroin addiction: rationale and design of the NAOMI study. Clin Trials 2009; 6: 261-271.
Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet 2010; 375: 1885-1895.
Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev 2011; 12: CD003410.
Blanken P, van den Brinck W, Hendriks V, Huijsman I, Klous M, Rook E et al. Heroin-assisted treatment in the Netherlands: history, findings, and international context. Eur Neuropsychopharmacol 2010; 20(2): 5105-5158.
Demaret I, Lemaître A, Ansseau M. L'efficacité du traitement assisté par diacétylmorphine (héroïne pharmaceutique) à l'étranger. Rev Med Liege 2010; 65: 681-687.
Pui-Nin Mo B, Leong Way E, An assessment of inhalation as a mode of administration of heroin by addicts. J Pharmacol Exp Ther 1966; 154(1): 142-151.
Strang J, Griffiths P, Gossop M. Heroin smoking by « chasing the dragon »: origins and history. Addiction 1997; 92(6): 673-683.
Rook E, Huitema A, van den Brinck W, van Ree J, Beijnen J. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol 2006; 1: 109-118.
Santolaria-Fernandez F, Gomez-Sirvent JL, Gonzalez-Reimers C, Batista-Lopez J, Jorge-Hernandez J, Rodriguez-Moreno F et al. Nutritional assessment of drug addicts, Drug Alcohol Depend 1995; 38: 11-18.
Piccolo P, Borg L, Lin A. Melia D, Ho A, Kreek MJ. Hepatitis C virus and human immunodeficiency virus-1 co-infection in former heroin addicts in methadone-maintenance treatment. J Addict Dis 2002; 21: 55-66.
Matheï C, Robaeys G, van Damme P, Buntinx F, Verrando R. Prevalence of hepatitis C in drug users in Flanders: determinants and geographic differences. Epidemiol Infect 2005; 133: 127-136.
Rook E, Hillebrand M, Rosing H, van Ree J, Beijnen J. The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry. J Chromatograph B Biomed Sci Appl 2005; 824: 213-221.
Dubois N, Debrus B, Hubert Ph, Charlier C. Validated quantitative simultaneous determination of cocaine, opiates and amphetamines in serum by U-HPLC coupled to tandem mass spectrometry. Acta Clin Belg Suppl 2010; 65(1): 75-84.
Rook E, Huitema A, van den Brinck W, van Ree J, Beijnen J. Population Pharmacokinetics of heroin and its major metabolites. Clin Pharmacokinet 2006; 45(4): 401-417.
Rook E, van Ree J, van den Brinck W, Hillebrand M, Huitema A, Hendricks V, Beijnen J. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic Clin Pharmacol Toxicol 2006; 98: 86-96.
Kamendulis L, Brzezinski M, Pindel E, Bosron W, Dean R. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J Pharmacol Exp Ther 1996; 279: 713-717.
Bruce R, Altice F, Gourevitch M, Friedland G. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 2006; 4: 563-572.
Polettini A., Groppi A., Montagna M. The role of alcohol abuse in heroin-related deaths. Evidence for pharmacokinetic interactions between heroin and alcohol. J Anal Toxicol 1999; 23(7): 570-576.
